{"id":"b5ed2f99b6af","type":"article","url":"https://hartvaat.nl/2026/01/20/uremie-en-bijschildklierhormoon-hebben-verschillende-effecten-op-boteiwit-en-gen/","title":"Uremie en bijschildklierhormoon hebben verschillende effecten op boteiwit en genexpressie","title_en":"Uremia and parathyroid hormone have distinct effects on bone protein and gene expression","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":["anemie-ckd","chronische-nierziekte","flow-trial","ijzertekort","vrouwen"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00006-2/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00006-2/fulltext","authors":["Carolina S. Wagner","Rosilene M. Elias","Thomas L. Nickolas","Aline Martin","Marta Martinez-Calle","Ivone B. Oliveira","Ana C. Coelho","Luciene M. dos Reis","Vanda Jorgetti","Valentin David","Rosa M.A. Moysés"],"significance":5,"published":"2026-01-20","source_date":"2026-01-20","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/nierziekte/contrastmiddel-en-nierfunctie/"],"congress":"","summary_en":"This study demonstrates that uraemia and parathyroid hormone exert distinct effects on bone protein and gene expression in CKD-associated osteoporosis. The findings have implications for treatment strategies beyond PTH management alone.","created":"2026-07-03T10:25:32Z","updated":"2026-07-03T13:24:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"CKD-geassocieerde osteoporose is zeer prevalent en verhoogt het fractuurrisico. Dit onderzoek toont dat uremie en bijschildklierhormoon verschillende effecten hebben op boteiwit en genexpressie, wat implicaties heeft voor het behandelbeleid.","abstract_original":"Chronic kidney disease (CKD)-associated osteoporosis is highly prevalent and increases the risk of fractures. Current therapy aims to preserve normal bone turnover, by maintaining parathyroid hormone (PTH) at relatively adequate levels. However, these patients continue to experience fractures."}